ANG Lifesciences India has executed an Asset purchase deal with Ind-Swift for acquisition of two formulation manufacturing facilities for Rs 60 crore. payable through internal accrual & bank funding on deferred payment basis up to June 30, 2024, located at Baddi (HP). The plants are now running as Unit 5 & Unit 6 of ANG Lifesciences India respectively. The said acquisition has helped in scaling up ANG’s manufacturing capacity to meet the growing demand from the domestic as well as international markets.
This acquisition is in line with ANG’s long-term strategic objective to become a complete Healthcare Solution Provider aimed at creating a broad-based basket of Pharmaceutical Formulation Products for a differentiated and comprehensive profile in pharmaceutical markets.
ANG Lifesciences India, incorporated in the year 2006, started with the business of manufacturing and marketing of finished pharmaceutical formulation in a dosage form of Sterile Dry Powder Injection Vial.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1486.55 |
Dr. Reddys Lab | 5860.25 |
Cipla | 1482.55 |
Zydus Lifesciences | 1072.35 |
Lupin | 1613.65 |
View more.. |